# China Plasma Fractionation Market

> China Plasma Fractionation Market Research Report By Product Type (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors), By Application (Neurology, Hematology, General Medicine, Immunology), By End User (Hospitals, Ambulatory Surgical Centers, Blood Banks, Pharmaceutical Companies) and By Technology (Centrifugation, Chromatography, Precipitation, Filtration) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.02%
- **2024:** $ 2,863.8 Million
- **2025:** $ 3,093.48 Million
- **2035:** $ 6,690 Million
- **Key Players:** Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company (JP), Octapharma (CH), Kedrion (IT), Biotest AG (DE), LFB Group (FR), Sangamo Therapeutics (US), Emergent BioSolutions (US)

**Report ID:** MRFR/HC/47618-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-plasma-fractionation-market-49368

---

## Market Summary

## **China Plasma Fractionation Market Overview**

As per MRFR analysis, the China Plasma Fractionation Market Size was estimated at 1.7 (USD Billion) in 2024.The China Plasma Fractionation Market Industry is expected to grow from 3(USD Billion) in 2025 to 6 (USD Billion) by 2035. The China Plasma Fractionation Market CAGR (growth rate) is expected to be around 6.504% during the forecast period (2025 - 2035).

**Key China Plasma Fractionation Market Trends Highlighted**

The China Plasma Fractionation Market is experiencing significant growth, driven by an increasing demand for immunoglobulins and a rising prevalence of chronic diseases. With China's aging population, there is a heightened focus on healthcare solutions, particularly for conditions requiring plasma-derived therapies. The government has been actively promoting initiatives to strengthen blood collection systems and improve the safety and quality of plasma products. This government support is crucial as it encourages investments in advanced technologies for plasma fractionation, leading to improved efficiency and effectiveness in product yield.

Opportunities in the China Plasma Fractionation Market are expanding as local players explore collaborations with global manufacturers to enhance their capabilities.There is a call for the establishment of more plasma collection centers across various provinces, which can help meet the growing domestic demand for plasma-derived therapies. Additionally, advancements in biotechnology are paving the way for innovative therapies based on plasma, creating a fertile ground for research and development. Companies are now focusing on utilizing these advancements to produce specialized immunoglobulin drugs, which opens new avenues for market expansion.

Recent trends highlight an increased emphasis on high-quality plasma products and compliance with international standards. In particular, as China aims to elevate its role in the global healthcare landscape, there is a push towards meeting stringent regulations that govern the plasma fractionation industry.This move not only ensures the safety of products but also fosters international partnerships. Overall, the China Plasma Fractionation Market reflects a dynamic landscape influenced by healthcare policy, technological advancements, and a growing focus on patient needs.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**China Plasma Fractionation Market Drivers**

**Increased Demand for Immunoglobulins**

The demand for immunoglobulins, crucial in treating immune deficiencies, has been escalating in China. The National Health Commission of the People's Republic of China reported that over 2 million people are diagnosed with primary immune deficiencies annually. This rising prevalence has significantly driven the growth of the China Plasma Fractionation Market Industry, as immunoglobulins are primarily derived from human plasma.

Organizations such as the Chinese Society of Blood Transfusion have noted a staggering 25% growth in immunoglobulin usage over the past five years, further indicating the growing reliance on these treatments.The increase in awareness and diagnosis of immunological disorders propels plasma fractionation as manufacturers strive to meet this surging demand, paving the way for advancements in processing technology and thereby expanding market opportunities within China.

**Supportive Government Policies**

China's government has been increasingly supportive of the biotechnology sector, particularly in blood product research and production. Recent policies have aimed at enhancing healthcare standards and ensuring the availability of life-saving blood products, including plasma-derived therapies. The Ministry of Health in China has set out clear guidelines and incentives for plasma collection and utilization in the healthcare system.

This has resulted in an increase in licensed plasma collection facilities, contributing positively to the China Plasma Fractionation Market Industry.Reports indicate that in 2023 alone, the establishment of new facilities rose by approximately 15%, thereby ensuring a robust supply chain for plasma and enhancing the overall market growth potential.

**Technological Advancements in Plasma Fractionation**

Innovations in plasma fractionation technologies have been pivotal in enhancing efficiency and output. Companies like Shanghai RAAS Blood Products Co., Ltd. have invested heavily in Research and Development (R&D) to improve the safety and efficacy of plasma-derived products. The introduction of continuous flow technologies and high-yield extraction methods has increased plasma processing capacity significantly. The China Food and Drug Administration reported that such advancements have reduced processing times by approximately 30% in recent years.

This transformation helps to increase the production volumes and, at the same time, meets the growing quality requirements of the customers in the China Plasma Fractionation Market Industry, which leads to significant growth of the market.

**Rising Incidences of Chronic Diseases**

The prevalence of chronic diseases such as diabetes and cardiovascular disorders in China is contributing to the expansion of the China Plasma Fractionation Market Industry. According to the Chinese Center for Disease Control and Prevention, around 11% of the population suffers from diabetes, leading to an increased need for immunotherapies, which often involve plasma derivatives.

This scenario calls for a proportional increase in plasma fractionation to supply essential treatments.As healthcare systems adapt to cater to these increasing numbers, manufacturers in the plasma fractionation industry are expected to see significant growth opportunities as they work to fulfill the demand for chronic disease management, making it a vital market driver.

**China Plasma Fractionation Market Segment Insights**

**Plasma Fractionation Market Product Type Insights**

The China Plasma Fractionation Market is witnessing notable developments within its Product Type segment, which includes various crucial components such as Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors. Immunoglobulin, being essential for the treatment of immunodeficiencies and autoimmune diseases, continues to significantly shape the market landscape.

The increasing prevalence of such conditions in China has led to a subsequent rise in demand for Immunoglobulin, establishing it as a leading product type within the market.Albumin, another vital product, plays a key role in critical care and surgical settings, often used for fluid replacement and maintaining oncotic pressure, thereby highlighting its importance in the healthcare sector. As healthcare facilities expand and adopt advanced therapeutic techniques, the demand for Albumin to grow, showcasing its significance in managing various clinical scenarios. Coagulation Factors are integral in treating hemophilia and other bleeding disorders.

Their importance is underscored by increasing awareness and diagnosis of such conditions, along with enhanced treatment protocols in China.Consequently, the rising incidence of clotting factor deficiencies has prompted healthcare providers to focus more on the availability and accessibility of these treatments. On the other hand, Protease Inhibitors are gaining attention due to their role in managing HIV and certain types of viral infections. With a substantial portion of the population affected by these health issues, the demand for Protease Inhibitors rises, ultimately contributing to the overall market growth.

The continuous advancements in technology related to plasma fractionation have also paved the way for improved product offerings, enabling manufacturers to cater effectively to the evolving needs of the healthcare sector. The collaboration between regulatory bodies and industry players has further strengthened the market infrastructure, ensuring that patients have access to high-quality plasma-derived therapies. As the industry progresses, significant opportunities arise, particularly around product innovation and improved plasma processing techniques, which are likely to shape the future dynamics of the China Plasma Fractionation Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Plasma Fractionation Market Application Insights**

The Application segment of the China Plasma Fractionation Market plays a crucial role in driving market growth, as it encompasses various fields such as Neurology, Hematology, General Medicine, and Immunology. Neurology applications utilize plasma-derived products to treat neurological disorders, reflecting the increasing demand for innovative therapies in China's aging population. In Hematology, the use of plasma fractions for treating blood disorders showcases the necessity of effective treatment solutions.

Meanwhile, General Medicine applications highlight the versatility of plasma products in enhancing patient care across multiple medical disciplines.Immunology remains a significant domain, focusing on immune therapies that are gaining traction in the healthcare landscape, driven by the rising prevalence of autoimmune diseases in China. The growing investments in Research and Development, coupled with supportive government initiatives, further underline the potential for advancements within these applications, paving the way for improved healthcare outcomes and contributing to the overall China Plasma Fractionation Market development.

The competitive landscape is also influenced by the increasing number of collaborations and partnerships among industry players aimed at enhancing product offerings and market reach.

**Plasma Fractionation Market End User Insights**

The China Plasma Fractionation Market is experiencing growth, driven by its diverse ser landscape which includes Hospitals, Ambulatory Surgical Centers, Blood Banks, and Pharmaceutical Companies. Hospitals are crucial as they serve as primary sites for plasma-derived therapies, addressing patient needs for various medical conditions. The presence of a growing aging population in China further amplifies the demand for plasma products in inpatient settings.

Ambulatory Surgical Centers are also significant, as they offer outpatient services that can enhance efficiency and reduce costs in plasma treatment administration.Blood Banks play a vital role in plasma donation and storage, thus directly impacting the availability of plasma-derived products, while Pharmaceutical Companies drive innovation and development in therapeutic solutions, ensuring a consistent supply through Research and Development investments. This diverse segmentation allows the market to leverage unique growth opportunities, aligning with wider trends such as increased awareness of plasma therapies and investments in biopharmaceuticals, ensuring sustained market progress in the region.

The regulatory environment in China also supports advancements in the plasma sector, helping establishments navigate compliance efficiently, which is essential for market growth.

**Plasma Fractionation Market Technology Insights**

The China Plasma Fractionation Market is experiencing significant growth in the Technology segment, driven by advancements in methodologies essential for effective plasma separation and purification. Among these methodologies, Centrifugation stands out as a widely adopted technique due to its efficiency in separating plasma components based on density differences. Chromatography is also gaining traction, recognized for its ability to achieve high specificity and purity, thereby enhancing product quality. Meanwhile, Precipitation methods are valued for their simplicity and cost-effectiveness, catering to different scale operations within laboratories and industrial settings.

Filtration techniques are critical in ensuring the removal of contaminants and achieving yield recovery rates in plasma fractions, making them vital for the production process. The interplay among these technologies not only boosts the overall efficacy of the plasma fractionation process but also aligns with the growing demand for blood-derived therapies across China, driven by an increasing prevalence of chronic diseases and the need for novel therapeutic solutions. As the industry evolves, these technologies play a significant role in meeting regulatory standards and improving the therapeutic effectiveness of plasma-derived products, thereby addressing both market challenges and consumer needs.

**China Plasma Fractionation Market Key Players and Competitive Insights**

The China Plasma Fractionation Market has been witnessing significant growth due to the increasing demand for immunoglobulin products and rising awareness related to plasma-derived therapies. With a vast population and a developing healthcare infrastructure, the market presents numerous opportunities for both domestic and international companies. The competitive landscape is characterized by the presence of established players and new entrants striving to enhance their market positions through innovation and strategic alliances. The growing aging population in China, alongside the prevalence of chronic diseases, is propelling the need for plasma derivatives, leading to intensified competition among key market participants.

Octapharma's presence in the China Plasma Fractionation Market is notable as the company continues to position itself as a leader in developing and providing high-quality human protein products. With a strong emphasis on research and development, Octapharma has been able to deliver a range of innovative plasmapheresis and immunotherapy products that cater to various medical needs. The company has built a robust distribution network throughout the region, gaining a competitive edge through its commitment to quality and regulatory compliance.

Additionally, Octapharma leverages its global expertise and local knowledge to adapt its offerings to meet the specific requirements of the Chinese market, which strengthens its foothold in this rapidly evolving sector. Hualan Biological Engineering has emerged as a significant player in the China Plasma Fractionation Market, focusing on the production of immunoglobulins, coagulation factors, and other plasma-derived products. The company is known for its strong operational capabilities, modern production facilities, and dedication to research and development.

Hualan has established a commendable market presence through strategic collaborations and partnerships aimed at enhancing its product range and increasing its distribution channels within China. Strengthened by a solid pipeline of products and a commitment to quality, Hualan is well-positioned to capitalize on the growing demand for plasma-derived therapies. The company's strategic mergers and acquisitions have further bolstered its capabilities, enabling it to expand its market share while continually improving its service offerings in the competitive arena of plasma fractionation.

**Key Companies in the China Plasma Fractionation Market Include**

- Octapharma
- Hualan Biological Engineering
- Grifols
- CSL Limited
- Kedrion S.p.A
- Zhejiang Hisun Pharmaceutical
- Baxter International
- Human Biologics
- Pfizer
- Shanxi Eryuan Biotech
- China National Pharmaceutical Group
- Sichuan Yuanda Shuyang Pharmaceutical
- Shanghai RAAS Blood Products

**China Plasma Fractionation Market Industry Developments**

In recent developments, the China Plasma Fractionation Market has seen notable activity, particularly with companies like Octapharma increasing their manufacturing capacity to meet rising domestic demand. Hualan Biological Engineering has made strides in expanding its portfolio of plasma-derived therapies, further solidifying its position in the market. Grifols has announced collaborations aimed at enhancing Research and Development initiatives in China, responding to the country's growing healthcare needs. Meanwhile, CSL Limited has reported a significant growth in market valuation, positively impacting their operational expansion within China.

Kedrion S.p.A has also engaged in strategic partnerships to boost its market presence. Noteworthy mergers include Zhejiang Hisun Pharmaceutical acquiring a smaller biotech firm in September 2023 to broaden its product offerings in the plasma sector and Shanghai RAAS Blood Products aiming at further integration into supply chains through investments in local production facilities last year. The overall market has been positively influenced by government policies promoting advancements in biotechnology, emphasizing blood product safety and production efficiency.

These developments underline a rapidly evolving landscape characterized by increased local investment and collaborative efforts among key players in the China Plasma Fractionation Market.

**China Plasma Fractionation Market Segmentation Insights**

**Plasma Fractionation Market Product Type****Outlook**

- Immunoglobulin
- Albumin
- Coagulation Factors
- Protease Inhibitors

**Plasma Fractionation Market Application****Outlook**

- Neurology
- Hematology
- General Medicine
- Immunology

**Plasma Fractionation Market End User****Outlook**

- Hospitals
- Ambulatory Surgical Centers
- Blood Banks
- Pharmaceutical Companies

**Plasma Fractionation Market Technology****Outlook**

- Centrifugation
- Chromatography
- Precipitation
- Filtration

## Market Drivers

### Surge in Chronic Diseases

The prevalence of chronic diseases in China is escalating, which significantly impacts the plasma fractionation market. Conditions such as hemophilia, immune deficiencies, and liver diseases are becoming more common, necessitating effective treatment options. According to recent statistics, approximately 10 million individuals in China suffer from hemophilia, creating a substantial demand for clotting factor concentrates. This surge in chronic diseases indicates a growing need for plasma-derived therapies, thereby driving the plasma fractionation market. As healthcare providers seek to address these health challenges, the reliance on plasma products is likely to increase. This trend may lead to enhanced research and development efforts aimed at improving plasma fractionation techniques, ultimately benefiting patients who require these life-saving treatments.

### Increasing Healthcare Expenditure

The rising healthcare expenditure in China is a pivotal driver for the plasma fractionation market. As the government allocates more funds towards healthcare, the demand for plasma-derived therapies is likely to increase. In 2023, healthcare spending in China reached approximately $1.2 trillion, reflecting a growth rate of around 10% annually. This trend suggests that more resources will be directed towards advanced medical treatments, including immunoglobulins and clotting factors derived from plasma. Consequently, the plasma fractionation market is expected to benefit from this increased investment, as healthcare facilities expand their capabilities to provide essential therapies. Furthermore, the growing awareness of plasma-derived products among healthcare professionals and patients may further stimulate market growth, as these therapies are crucial for treating various medical conditions.

### Expansion of Plasma Collection Centers

The establishment of new plasma collection centers across China is a crucial driver for the plasma fractionation market. In recent years, the government has encouraged the development of these centers to ensure a steady supply of plasma for therapeutic use. As of 2025, there are over 200 licensed plasma collection facilities in China, with plans for further expansion. This growth is essential for meeting the rising demand for plasma-derived products, as it enhances the availability of raw materials for fractionation processes. The plasma fractionation market stands to gain from this expansion, as increased plasma collection directly correlates with the production of immunoglobulins and other critical therapies. Moreover, public awareness campaigns promoting plasma donation are likely to bolster the supply chain, ensuring that the market can sustain its growth trajectory.

### Regulatory Support for Plasma Products

Regulatory support for plasma-derived products in China is a vital driver for the plasma fractionation market. The government has implemented favorable policies to streamline the approval process for new therapies, ensuring that safe and effective plasma products reach the market more efficiently. Recent regulatory reforms have reduced the time required for clinical trials and product approvals, which is likely to encourage investment in the plasma fractionation market. As a result, pharmaceutical companies may be more inclined to develop innovative therapies based on plasma proteins. This supportive regulatory environment not only enhances market accessibility but also fosters competition among manufacturers, potentially leading to improved product offerings for patients. The ongoing commitment to regulatory excellence is expected to sustain the growth of the plasma fractionation market in the coming years.

### Advancements in Research and Development

Ongoing advancements in research and development within the plasma fractionation market are driving innovation and efficiency. Chinese research institutions and pharmaceutical companies are increasingly investing in R&D to enhance fractionation technologies and improve product yields. For instance, novel purification techniques and automated processes are being explored to optimize the extraction of valuable plasma proteins. This focus on innovation is expected to lead to higher-quality products and reduced production costs, thereby benefiting the plasma fractionation market. Furthermore, collaborations between academic institutions and industry players are fostering a conducive environment for breakthroughs in plasma therapies. As these advancements materialize, they may significantly enhance the therapeutic options available to patients, ultimately contributing to the market's growth.

## Future Outlook

The [Plasma Fractionation Market](https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397) in China is projected to grow at an 8.02% CAGR from 2025 to 2035, driven by increasing demand for immunoglobulins and advancements in technology.

**New opportunities:**

- Expansion of contract manufacturing services for biopharmaceutical companies.
- Development of innovative plasma-derived therapies targeting rare diseases.
- Investment in automated plasma collection and processing technologies.

By 2035, the plasma fractionation market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Immunology (Largest) vs. Neurology (Fastest-Growing)

In the China plasma fractionation market, the distribution of market share among application segments is quite diverse. Immunology holds the largest share, driven by the increasing demand for immunoglobulins and other immunotherapy products. Neurology, while currently smaller in market share, is rapidly gaining traction due to growing awareness and investment in neurological disorders treatment options.

Growth trends in this segment are notably influenced by innovation in drug development and increasing prevalence of related health conditions. The rising geriatric population and better diagnostic techniques are propelling the growth of neurology applications. Moreover, advancements in technology and enhancements in plasma collection techniques are driving efficiency, thus attracting more investments in the plasma fractionation processes across these application segments.

Hematology (Dominant) vs. General Medicine (Emerging)

Hematology stands as a dominant force within the China plasma fractionation market, primarily due to its critical role in managing blood-related disorders and the high demand for blood plasma components. This segment focuses on providing essential therapies for various hematological issues, benefiting from extensive research and clinical experience. On the other hand, General Medicine is emerging as a significant contender, tapping into broader healthcare needs such as wound healing and surgical applications. As healthcare systems evolve and focus on patient-centric solutions, General Medicine is projected to grow, gaining attention from manufacturers and investors seeking diversified opportunities within the plasma fractionation market.

### By Product Type: Immunoglobulin (Largest) vs. Albumin (Fastest-Growing)

The market share distribution among segment values indicates that Immunoglobulin holds a significant position, driven by its extensive use in various therapeutic areas, particularly immunodeficiencies. Albumin follows closely, recognized for its applications in critical care and surgery, making it a vital component in treatment protocols. Coagulation Factors and Protease Inhibitors, while essential, maintain smaller shares compared to these leading products. The current landscape showcases a compelling divergence in the usage and demand for these products, reflecting their respective roles in healthcare.

Growth trends in the product type segment signal a robust future for Albumin as it witnesses increasing demand due to its emerging applications in novel therapies. The rise in aging populations coupled with a surge in chronic diseases is fueling the need for Immunoglobulin as well. Enhanced awareness regarding rare diseases is also driving the market, particularly in the context of disease management, which propels the consumables that cater to both preventive and therapeutic needs.

Immunoglobulin: Dominant vs. Albumin: Emerging

Immunoglobulin remains the dominant product in the China plasma fractionation market, largely due to its critical role in treating autoimmune disorders and immunodeficiencies. Its broad application spectrum solidifies its status, making it a preferred choice among healthcare providers. On the other hand, Albumin is identified as an emerging player, gaining traction for its versatile use in fluid resuscitation and as a carrier for drug delivery. The increasing emphasis on targeted therapies and personalized medicine enhances Albumin's attractiveness, leading to its fast growth. The combined characteristics of these products showcase a dynamic interplay of established dominance and emerging opportunities, which are pivotal for driving innovation and meeting patient needs.

### By End User: Hospitals (Largest) vs. Blood Banks (Fastest-Growing)

In the China plasma fractionation market, hospitals hold the largest market share among the end users, driven by a high demand for plasma-derived therapies and treatments. Blood banks, while smaller in scale, are rapidly growing due to increasing awareness of blood donation's significance and advancements in plasma processing technologies.

The growth in the hospital segment is influenced by the rising incidence of chronic diseases and the subsequent demand for therapeutic plasma products. On the other hand, blood banks are expected to experience the fastest growth, primarily due to increased governmental support for blood donation initiatives and advancements in fractionation technology that enhance plasma collection and processing efficiency.

Hospitals (Dominant) vs. Pharmaceutical Companies (Emerging)

Hospitals remain the dominant end-user in the plasma fractionation market, characterized by extensive facilities and a high volume of patient services, which fuel their reliance on plasma-derived therapies. They are well-equipped to utilize these therapies in various medical applications, significantly contributing to patient care. In contrast, pharmaceutical companies are emerging as a vital segment in this market, focusing on the development and commercialization of innovative plasma products. Their growth is driven by a surge in research and development activities, coupled with strategic partnerships and mergers, aimed at expanding therapeutic options available on the market. Between these two segments, hospitals leverage their established infrastructure, whereas pharmaceutical companies bring novel solutions to market, creating a balanced yet competitive environment.

### By Technology: Centrifugation (Largest) vs. Chromatography (Fastest-Growing)

In the China plasma fractionation market, the distribution of market share among the technology segment values demonstrates a clear hierarchy. Centrifugation holds a dominant position, representing the largest share due to its efficiency and established technology in separating plasma components. Chromatography, while having a smaller share, is noted for its rapid growth and innovation, as more companies adopt advanced separation techniques to improve yield and purity.

Growth trends indicate a rising demand for plasma-derived products that are fostering investment in technology advancements. The continuous expansion of the biopharmaceutical sector and increasing prevalence of chronic diseases are critical drivers. Furthermore, regulatory support for safety and efficacy in plasma processing techniques propels companies to enhance their operational capabilities, leading to increased adoption of faster and more efficient technologies like chromatography.

Technology: Centrifugation (Dominant) vs. Chromatography (Emerging)

Centrifugation is recognized as the dominant technology in the plasma fractionation process due to its ability to achieve high separation efficiencies without compromising product integrity. It leverages centrifugal force to segregate plasmic components effectively, making it a staple in many production facilities. Meanwhile, chromatography is emerging as a crucial technology, gaining traction thanks to its precision and adaptability. It allows for more refined separation processes that cater to specific product requirements. The shift towards high-purity plasma products is creating a favorable environment for chromatography's expansion, as it complements traditional methods and addresses challenges like contamination and product variability.

## Competitive Benchmarking

The plasma fractionation market in China is characterized by a dynamic competitive landscape, driven by increasing demand for immunoglobulins and clotting factors, alongside a growing emphasis on advanced therapeutic solutions. Key players such as Grifols (ES), CSL Behring (AU), and Takeda Pharmaceutical Company (JP) are strategically positioned to leverage their extensive product portfolios and innovative capabilities. Grifols (ES) focuses on expanding its manufacturing footprint in Asia, which appears to enhance its supply chain efficiency and market reach. Meanwhile, CSL Behring (AU) emphasizes partnerships with local healthcare providers to improve patient access to therapies, thereby solidifying its market presence. Takeda Pharmaceutical Company (JP) is actively pursuing digital transformation initiatives, which may streamline operations and enhance customer engagement, collectively shaping a competitive environment that prioritizes innovation and responsiveness.The business tactics employed by these companies reflect a concerted effort to localize manufacturing and optimize supply chains, which is crucial in a moderately fragmented market. This structure allows for a diverse range of offerings while enabling key players to exert significant influence over pricing and distribution channels. The collective strategies of these companies suggest a trend towards consolidation, as they seek to enhance operational efficiencies and market share through strategic collaborations and investments.

In September  Grifols (ES) announced the opening of a new plasma collection center in Shanghai, which is expected to significantly increase its plasma supply capabilities. This strategic move not only enhances Grifols' operational capacity but also aligns with the growing demand for plasma-derived therapies in the region. The establishment of this center may position Grifols to better serve the local market and respond to the increasing healthcare needs of the population.

In October  CSL Behring (AU) entered into a partnership with a leading Chinese biotechnology firm to co-develop novel therapies for rare diseases. This collaboration is indicative of CSL Behring's commitment to innovation and its strategy to tap into the burgeoning biopharmaceutical sector in China. By leveraging local expertise, CSL Behring may accelerate the development of new treatments, thereby enhancing its competitive edge in the market.

In August  Takeda Pharmaceutical Company (JP) launched a new digital platform aimed at improving patient engagement and education regarding plasma therapies. This initiative reflects Takeda's focus on digitalization as a means to enhance customer experience and streamline communication. The platform is likely to foster greater awareness and understanding of plasma-derived products, potentially leading to increased adoption and market penetration.

As of November  the competitive trends in the plasma fractionation market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving operational efficiencies. Looking ahead, competitive differentiation is expected to evolve, with a shift from traditional price-based competition towards a focus on technological advancements, innovative therapies, and reliable supply chains. This transition may ultimately reshape the market dynamics, fostering a landscape where companies that prioritize innovation and sustainability are likely to thrive.

## Recent News & Developments

In recent developments, the China Plasma Fractionation Market has seen notable activity, particularly with companies like Octapharma increasing their manufacturing capacity to meet rising domestic demand. Hualan Biological Engineering has made strides in expanding its portfolio of plasma-derived therapies, further solidifying its position in the market. Grifols has announced collaborations aimed at enhancing Research and Development initiatives in China, responding to the country's growing healthcare needs. Meanwhile, CSL Limited has reported a significant growth in market valuation, positively impacting their operational expansion within China.

Kedrion S.p.A has also engaged in strategic partnerships to boost its market presence. Noteworthy mergers include Zhejiang Hisun Pharmaceutical acquiring a smaller biotech firm in September 2023 to broaden its product offerings in the plasma sector and Shanghai RAAS Blood Products aiming at further integration into supply chains through investments in local production facilities last year. The overall market has been positively influenced by government policies promoting advancements in biotechnology, emphasizing blood product safety and production efficiency.

These developments underline a rapidly evolving landscape characterized by increased local investment and collaborative efforts among key players in the China Plasma Fractionation Market.

## Report Scope

| MARKET SIZE 2024 | 2863.8(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 3093.48(USD Million) |
| MARKET SIZE 2035 | 6690.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.02% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company (JP), Octapharma (CH), Kedrion (IT), Biotest AG (DE), LFB Group (FR), Sangamo Therapeutics (US), Emergent BioSolutions (US) |
| Segments Covered | Application, Product Type, End User, Technology |
| Key Market Opportunities | Advancements in plasma-derived therapies drive growth in the plasma fractionation market. |
| Key Market Dynamics | Rising demand for immunoglobulins drives innovation and competition in the plasma fractionation market. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What was the overall market valuation of the China plasma fractionation market in 2024?**
A: The overall market valuation was $2863.8 Million in 2024.

**Q: What is the projected market valuation for the China plasma fractionation market by 2035?**
A: The projected valuation for 2035 is $6690.0 Million.

**Q: What is the expected CAGR for the China plasma fractionation market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 8.02%.

**Q: Which application segment had the highest valuation in 2024?**
A: The General Medicine application segment had the highest valuation, ranging from $1000.0 Million to $2500.0 Million.

**Q: What are the projected valuations for the Immunoglobulin product type by 2035?**
A: The projected valuation for the Immunoglobulin product type is expected to range from $1140.0 Million to $2700.0 Million.

**Q: Which end user segment is anticipated to show significant growth by 2035?**
A: The Hospitals end user segment is anticipated to show significant growth, with a projected valuation from $1145.52 Million to $2670.0 Million.

**Q: What technology segment is expected to have the highest valuation by 2035?**
A: The Chromatography technology segment is expected to have the highest valuation, projected to range from $900.0 Million to $2100.0 Million.

**Q: Who are the key players in the China plasma fractionation market?**
A: Key players include Grifols, CSL Behring, Takeda Pharmaceutical Company, Octapharma, and others.

**Q: What is the valuation range for the Hematology application segment in 2024?**
A: The Hematology application segment had a valuation range from $800.0 Million to $1800.0 Million in 2024.

**Q: How does the projected growth of the China plasma fractionation market compare to its 2024 valuation?**
A: The market is expected to grow from $2863.8 Million in 2024 to $6690.0 Million by 2035, indicating substantial growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-plasma-fractionation-market-49368*